Top story

U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

SAN CARLOS, Calif.--(BUSINESS WIRE) November 26, 2025 -- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and …

Read full story

Tris Pharma Announces Positive Results from ALLEVIATE-1 Phase 3 Clinical Trial of Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain

PharmaProLearn News
Wed, 22 Jan 2025
Read more

Zydus Announces USFDA Orphan Drug Designation to Usnoflast for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

PharmaProLearn News
Wed, 22 Jan 2025
Read more